Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.
…
The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services
…
Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care.
A new study in Health Affairs could add to the squeeze on 340B hospitals’ margins on infused cancer drugs.
Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.
Hospitals participating in the 340B program provided $67.9 billion in total benefits to their communities in 2018, the American Hospital Association (AHA) reported yesterday.
Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.
Meanwhile, two longtime 340B program policy
…
Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports. Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic
…Sign up for news summaries and alerts from 340B Report
